Results 61 to 70 of about 2,075,366 (204)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis

International Journal of Cardiology: Heart & Vasculature
Background: Due to overlapping symptoms and signs, it can be challenging to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM) in the setting of concomitant aortic stenosis.
Margrethe Flesvig Holt, Annika E. Michelsen, August Flø, Kristoffer Russell, Jan Otto Beitnes, Sophie Foss Kløve, Anders Hodt, Lars Gullestad, Pål Aukrust, Einar Gude, Kaspar Broch, Thor Ueland   +11 more
doaj   +1 more source

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Transthyretin cardiac amyloidosis (ATTR‐CM), found in 6% to 15% of cohorts with heart failure with preserved ejection fraction, has long been considered a rare disease with poor prognosis.
Morris M. Kim, Mark Prasad, Yunwoo Burton, Clinton M. Kolseth, Yuanzi Zhao, Pranav Chandrashekar, Babak Nazer, Ahmad Masri   +7 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation

ESC Heart Failure
Aims The prevalences of aortic stenosis (AS) and transthyretin amyloid cardiomyopathy (ATTR‐CM) increase with age. Identification of occult ATTR‐CM in patients with AS can help explain out‐of‐proportion myocardial dysfunction, aid in prognostication and ...
Margrethe Flesvig Holt, August Flø, Esra Kaya, Sophie Foss Kløve, Hege Martinsen, Kristine Amlie, Petter Storsten, Thomas Misje Mathiisen, Kristoffer Russell, Christian Hesbø Eek, Helge Skulstad, Melinda Raki, Lars Gullestad, Anders Hodt, Einar Gude, Kaspar Broch   +15 more
doaj   +1 more source

Systemic Embolism in Amyloid Transthyretin Cardiomyopathy [PDF]

, 2022
Aims: Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR-CM), data about its incidence and prevalence are scarce.
Caponetti, Angelo, De Los Santos, Jeffeny, Dominguez, Fernando, Fontana, Marianna, Gagliardi, Christian, Garcia-Pavia, Pablo, Gillmore, Julian, Gnanasampanthan, Sahana, Gonzalez-Lopez, Esther, Griffin, Jan M, Longhi, Simone, Maurer, Mathew S, Mitrani, Lindsey, Rapezzi, Claudio, Renju, Mary, Rivas, Adrian, Saturi, Giulia, Vilches, Silvia   +17 more
core  

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

ESC Heart Failure, 2021
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) was the first large clinical trial to include both wild‐type (ATTRwt)
Jose Nativi‐Nicolau, Daniel P. Judge, James E. Hoffman, Balarama Gundapaneni, Denis Keohane, Marla B. Sultan, Martha Grogan   +6 more
doaj   +1 more source

Biomarkers to Predict Abnormal Technetium-99m Pyrophosphate Scans in Patients With Suspected Transthyretin Amyloidosis [PDF]

Background: Technetium Tc 99m pyrophosphate scintigraphy (99mTc PYP imaging) is a diagnostic tool for transthyretin amyloid cardiomyopathy (ATTR-CM). Cardiac biomarkers, particularly high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro–B-type ...
Abbasi, Muhannad A, AbouEzzeddine, Omar F, Davies, Daniel R, De Michieli, Laura, Dispenzieri, Angela, Grogan, Martha, Jaffe, Allan S, Muchtar, Eli, Redfield, Margaret M, Scott, Christopher G   +9 more
core   +1 more source